Group | N | Observed, n (%) | Expected, n (%) | SMR | (95 % CI) | p-value (log-rank) |
---|---|---|---|---|---|---|
All patients | 1388 | 291 (21.0) | 107.3 (7.7) | 2.7 | 2.4 to 3.0 | <0.0001 |
Gender | 0.0009 | |||||
Male | 533 | 131 (24.6) | 52.6 (9.9) | 2.5 | 2.1 to 2.9 | |
Female | 855 | 160 (18.7) | 54.7 (6,4) | 2.9 | 2.5 to 3.4 | |
Course of disease at onset | <0.0001 | |||||
RRMS | 1209 | 202 (16.7) | 84.4 (7.0) | 2.4 | 2.1 to 2.7 | |
PPMS | 179 | 89 (49.7) | 23.0 (12.8) | 3.9 | 3.1 to 4.7 | |
Period for onset | 0.0083 | |||||
1953–1974 | 237 | 155 (65.4) | 49.8 (21.0) | 3.1 | 2.6 to 3.6 | |
1975–1996 | 638 | 130 (20.4) | 49.4 (7.7) | 2.6 | 2.2 to 3.1 | |
1997–2012 | 513 | 6 (1.1) | 8.1 (1.6) | 0.7 | 0.3 to 1.5 | |
Period for diagnosis | <0.0001 | |||||
1953–1974 | 136 | 100 (73.5) | 33.4 (24.6) | 3 | 2.5 to 3.6 | |
1975–1996 | 602 | 178 (29.6) | 58.3 (9.7) | 3.1 | 2.6 to 3.5 | |
1997–2012 | 650 | 13 (2.0) | 15.7 (2.4) | 0.8 | 0.5 to 1.4 | |
Age at onset (years) | <0.0001 | |||||
20 | 107 | 20 (18.7) | 2.7 (2.5) | 7.3 | 4.5 to 10.9 | |
21–30 | 471 | 90 (19.1) | 22.3 (4.7) | 4 | 3.3 to 4.9 | |
31–40 | 459 | 90 (19.6) | 35.2 (7.7) | 2.6 | 2.1 to 3.1 | |
41–50 | 246 | 61 (13.4) | 28.2 (6.2) | 2.2 | 1.7 to 2.8 | |
51–60 | 92 | 25 (27.2) | 15.0 (16.3) | 1.7 | 1.1 to 2.4 | |
61+ | 13 | 5 (38.5) | 3.9 (3.0) | 1.3 | 0.5 to 2.8 | |
Age at diagnosis (years) | 0.0043 | |||||
20 | 49 | 6 (12.2) | 0. 7 (1.4) | 9 | 3.6 to 18.3 | |
21–30 | 327 | 57 (17.4) | 10.6 (3.2) | 5.4 | 4.1 to 6.9 | |
31–40 | 454 | 90 (19.8) | 25.5 (5.6) | 3.5 | 2.9 to 4.3 | |
41–50 | 356 | 81 (22.8) | 37.0 (10.4) | 2.2 | 1.7 to 2.7 | |
51–60 | 161 | 42 (26.1) | 24.3 (15.1) | 1.7 | 1.3 to 2.3 | |
61+ | 41 | 15 (36.6) | 9.2 (22.4) | 1.6 | 0.9 to 2.6 |
PPMS, primary progressive MS; RRMS, relapsing-remitting MS.